Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Follitropin Delta→

Follitropin Delta Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
146479-72-3
Molecular formula
Not available
Molecular weight
~30000 g/mol
Drug class
Recombinant human follicle-stimulating hormone (FSH) gonadotropin
Mechanism of action
Activates FSH receptors on ovarian granulosa cells to stimulate follicular growth and development. It has the amino-acid sequence of endogenous human FSH and a distinct glycosylation profile because it is produced in the human PER.C6 cell line.
Indications / reported uses
  • Controlled ovarian stimulation to develop multiple follicles in women undergoing assisted reproductive technologies such as IVF or ICSI; the dose is individualised and expressed in micrograms, not interchangeable with IU doses of other gonadotropins

Sources: EMA EPAR — Rekovelle · EMA product information — Rekovelle (updated 29 Jun 2026) · UK SmPC — Rekovelle · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Follitropin Delta Environmental Risk Assessment (ERA) (the Follitropin Delta ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.